# Soleno Therapeutics, Inc.

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/soleno-therapeutics-inc
Canonical HTML page: https://getyourbrief.com/entity/soleno-therapeutics-inc

## Timeline

- **2026-Q3**: Lead Counsel Appointment — Expected timeframe for the court to designate the lead plaintiff and legal representation.
- **2026-05-11**: Lead Plaintiff Deadline — Final day for affected investors to petition the court to lead the class action.
- **2026-03-12**: Lawsuit Announcements — Schall Law Firm files class action notices for Soleno Therapeutics and Ultragenyx Pharmaceutical.
- **2026-03-12**: Litigation Commencement — Schall Law Firm announces class action lawsuits against both SLNO and RARE.
- **2026-02-26**: Soleno Executive Turnover — Official filing confirms the departure of several directors and officers.
- **2026-02-25**: Soleno Financial Results — Soleno files annual results and operational updates.
- **2026-02-12**: Ultragenyx Restructuring Disclosure — Company files SEC report detailing costs for exit or disposal activities.

## Recent coverage (3 stories, network-wide)

### Schall Law Firm Targets Soleno and Ultragenyx in Securities Fraud Litigation
2026-03-12 10:06:11 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

The Schall Law Firm has initiated securities fraud class action lawsuits against biotech players Soleno Therapeutics and Ultragenyx Pharmaceutical. The legal actions follow a series of corporate disclosures in early 2026, inviting impacted investors to lead the litigation efforts.
Full story: https://getbiobrief.com/story/soleno-ultragenyx-securities-fraud-lawsuits-schall

### Soleno and Ultragenyx Face Securities Fraud Litigation Over Disclosure Risks
2026-03-12 10:05:39 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

The Schall Law Firm has initiated securities fraud class action lawsuits against rare disease biotechs Soleno Therapeutics and Ultragenyx Pharmaceutical. These legal challenges highlight the heightened scrutiny on clinical data transparency and regulatory communications in the high-stakes orphan drug sector.
Full story: https://gethealthbrief.com/story/soleno-ultragenyx-securities-fraud-lawsuits-2026

### Schall Law Firm Targets Soleno and Ultragenyx in Dual Securities Fraud Actions
2026-03-12 10:04:00 · Sector: legal · Sentiment: Neutral · Impact: 5/10 · Sources: 2

The Schall Law Firm has initiated securities fraud class actions against Soleno Therapeutics and Ultragenyx Pharmaceutical, alleging violations of federal securities laws. The firm is currently seeking lead plaintiffs to represent the class in these high-stakes biotech litigations following potential misrepresentations to the market.
Full story: https://getlegalbrief.com/story/schall-law-firm-soleno-ultragenyx-securities-fraud

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.